

# Development of treatment for drug-resistant cancer patients at the stage 4

| ONCOLOGY                 | Hit   |
|--------------------------|---|
| Product Type             | Small molecules   |
| Indication               | cisplatin-resistant solid tumor                                   |
| Target                   | DNA AP-site   |
| MoA(Mechanism of Action) | DNA-damaging agents   |
| Competitiveness          | First-in-class<br>cisplatin-based drug-resistant anticancer drugs |
| Development Stage        | Hit   |
| Route of Administration  | Oral administration or IV injection                               |